SG Americas Securities LLC lessened its holdings in Boston Scientific Corporation (NYSE:BSX) by 51.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 62,227 shares of the medical equipment provider’s stock after selling 66,003 shares during the period. SG Americas Securities LLC’s holdings in Boston Scientific were worth $1,815,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of the stock. Janus Henderson Group PLC grew its stake in Boston Scientific by 22,491.6% during the second quarter. Janus Henderson Group PLC now owns 38,862,599 shares of the medical equipment provider’s stock worth $1,077,270,000 after buying an additional 38,690,577 shares during the last quarter. Jennison Associates LLC grew its stake in Boston Scientific by 405.3% during the second quarter. Jennison Associates LLC now owns 10,639,290 shares of the medical equipment provider’s stock worth $294,921,000 after buying an additional 8,533,655 shares during the last quarter. BlackRock Inc. grew its stake in Boston Scientific by 4.6% during the second quarter. BlackRock Inc. now owns 100,184,511 shares of the medical equipment provider’s stock worth $2,777,113,000 after buying an additional 4,439,966 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. grew its stake in Boston Scientific by 35,016.2% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock worth $84,337,000 after buying an additional 3,033,800 shares during the last quarter. Finally, Prudential Financial Inc. grew its stake in Boston Scientific by 149.1% during the third quarter. Prudential Financial Inc. now owns 4,762,674 shares of the medical equipment provider’s stock worth $138,928,000 after buying an additional 2,850,630 shares during the last quarter. 90.68% of the stock is owned by hedge funds and other institutional investors.
In other news, EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $26.87, for a total transaction of $416,485.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Timothy A. Pratt sold 10,104 shares of the stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $27.46, for a total transaction of $277,455.84. Following the sale, the executive vice president now directly owns 185,742 shares in the company, valued at $5,100,475.32. The disclosure for this sale can be found here. Insiders have sold 508,864 shares of company stock worth $14,581,669 over the last three months. 0.74% of the stock is owned by insiders.
BSX has been the topic of several research analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a research note on Sunday, July 30th. Jefferies Group LLC reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Thursday, September 7th. BMO Capital Markets reaffirmed a “buy” rating and set a $30.00 price objective on shares of Boston Scientific in a research note on Friday, October 13th. Canaccord Genuity initiated coverage on shares of Boston Scientific in a research note on Tuesday, October 24th. They set a “buy” rating and a $36.00 price objective on the stock. Finally, Zacks Investment Research cut shares of Boston Scientific from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. One analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. Boston Scientific has a consensus rating of “Buy” and a consensus price target of $30.77.
Shares of Boston Scientific Corporation (BSX) opened at $28.66 on Friday. Boston Scientific Corporation has a 52 week low of $19.67 and a 52 week high of $29.93. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. The company has a market cap of $39,355.80, a P/E ratio of 23.49, a PEG ratio of 2.21 and a beta of 1.00.
Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.31. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The business had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the prior year, the firm earned $0.27 earnings per share. Boston Scientific’s revenue was up 5.6% compared to the same quarter last year. analysts anticipate that Boston Scientific Corporation will post 1.25 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “SG Americas Securities LLC Sells 66,003 Shares of Boston Scientific Corporation (BSX)” was first reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://transcriptdaily.com/2017/11/26/sg-americas-securities-llc-sells-66003-shares-of-boston-scientific-corporation-bsx.html.
Boston Scientific Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.